• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The CHOIR trial: Target lower hemoglobin levels in patients with anemia and chronic kidney disease [Classics Series]

bys25qthea
July 21, 2013
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/L. academia

1. In patients with anemia and chronic kidney disease, treating with epoetin alfa to a lower hemoglobin target was associated with significantly reduced incidence of the composite event (death, MI, hospitalization for CHF, and stroke).

2. Achieving the lower hemoglobin target required significantly lower doses of epoetin alfa.

Study Rundown: These findings suggest that in patients with anemia and chronic kidney disease, treating with epoetin alfa to a higher hemoglobin target is linked with a significantly higher risk of negative events (i.e., death, MI, hospitalization for CHF, stroke) when compared to a lower target. Moreover, achieving the higher target requires about double the dose of epoetin alfa, which is quite a costly medication. While this study is a multicentre, randomized trial, it was been criticized for its relatively small size, high rates of withdrawal from the study, and the fact that it was not double-blinded.

In sum, treating anemia in patients with chronic kidney disease using epoetin alfa to a lower hemoglobin target (i.e., ≥11.3 g/dL) was associated with a significantly lower risk of composite events compared to a high target (i.e., ≥13.5 g/dL). Significantly lower doses of epoetin alfa are required to achieve the lower hemoglobin target.

Please click to read the study in NEJM

In Depth [randomized, controlled study]: The CHOIR trial, initially published in 2006 in NEJM, was an open-label, randomized study exploring the use of epoetin alfa in treating anemia associated with chronic kidney disease. The trial sought to determine if treating with epoetin alfa to target a higher hemoglobin level (i.e., ≥13.5 g/dL) would improve outcomes when compared to a lower target (i.e., ≥11.3 g/dL). The targets were adjusted partway through the trial, as the initial targets were 13.0-13.5 g/dL for the high-hemoglobin group and 10.5-11.0 g/dL for the low-hemoglobin group. Patients were included if they were at least 18 years of age, had a hemoglobin <11.0 g/dL, and had chronic kidney disease (i.e., GFR 15-50 ml/min/1.73m2 using MDRD). The primary endpoint was the time to a composite of death, myocardial infarction (MI), hospitalization for congestive heart failure (CHF), or stroke.

RELATED REPORTS

Racial and ethnic discrepancies in pulse oximetry performance associated with reduced oxygen supplementation

Discrepancies exist between measured and estimated glomerular filtration rate

Comparisons of invasive versus conservative management in chronic kidney disease in the ISCHEMIA-CKD trials

The study was terminated early in May 2005 at the second interim analysis on the recommendation of the data and safety monitoring board. At that time, a total of 1,432 participants had been enrolled from 130 states from across the United States, with 715 in the high-hemoglobin group and 717 in the low-hemoglobin group. Analyses were based on intention-to-treat, though a total of 549 (38.3%) patients withdrew from the study prematurely. There was a significantly increased risk of composite event in the high-group compared to the low-group (HR 1.34; 95% CI 1.03-1.74). Of note, death (29.3%) and hospitalization for CHF (45.5%) accounted for 74.8% of the composite events. It was also noted that patients in the high-group required almost double the dose of epoetin alfa to achieve the target when compared to the dose required to achieve the low-target.

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: anemiachoir trialchronic kidney diseasehemoglobin
Previous Post

Active phase of labor longer in twin deliveries

Next Post

The CREST trial: Stenting versus endarterectomy for carotid stenosis [Classics Series]

RelatedReports

Lower target oxygen saturation in extremely preterm infants appears safe
Critical, Emergent and Pulmonary Care Classics

Racial and ethnic discrepancies in pulse oximetry performance associated with reduced oxygen supplementation

July 22, 2022
Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

Discrepancies exist between measured and estimated glomerular filtration rate

July 18, 2022
Being overweight and obese associated with increased incidence of chronic kidney disease
Cardiology

Comparisons of invasive versus conservative management in chronic kidney disease in the ISCHEMIA-CKD trials

July 7, 2022
Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Uric acid-lowering therapy not associated with improved kidney function

June 13, 2022
Next Post

The CREST trial: Stenting versus endarterectomy for carotid stenosis [Classics Series]

2 Minute Medicine Rewind: July 15 – July 21, 2013

2 Minute Medicine Rewind: July 15 – July 21, 2013

Costs for DKA care vary significantly among U.S. hospitals

Costs for DKA care vary significantly among U.S. hospitals

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dulaglutide improves glycemic control for youth with type 2 diabetes
  • Cinpanemab therapy does not prevent Parkinson’s disease progression
  • Criteria for low-dose computed tomography lung cancer screening omit a high risk population of smokers
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.